TY - JOUR T1 - Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early <em>Versus</em> Delayed Administration JF - Anticancer Research JO - Anticancer Res SP - 5877 LP - 5881 DO - 10.21873/anticanres.12930 VL - 38 IS - 10 AU - FRANCESCO PASQUALETTI AU - ALESSANDRA GONNELLI AU - ALESSANDRO MOLINARI AU - MARTINA CANTARELLA AU - SABRINA MONTRONE AU - AGOSTINO CRISTAUDO AU - DAVIDE BALDACCINI AU - ROBERTO MATTIONI AU - DURIM DELISHAJ AU - VALENTINA MAZZOTTI AU - RICCARDO MORGANTI AU - PAOLA COCUZZA AU - MARIA GRAZIA FABRINI AU - GIUSEPPE LOMBARDI AU - ROBERTA RUDÀ AU - RICCARDO SOFFIETTI AU - FABIOLA PAIAR Y1 - 2018/10/01 UR - http://ar.iiarjournals.org/content/38/10/5877.abstract N2 - Background/Aim: In patients with recurrent glioblastoma, the best timing to administer bevacizumab is not well addressed yet. In this study, we reported the results of a monocentric experience comparing the early use of bevacizumab (following the first GBM recurrence) with the delayed administration (following the second or even further GBM recurrences). Materials and Methods: This analysis included 129 glioblastoma patients with a median follow-up of 22.4 months (range=5.26-192 months). Results: The median time lapse from diagnosis of glioblastoma to disease recurrence was 11.6 months; 13.1 for patients treated with deferred administration of bevacizumab and 9.9 for patients with early administration (p=0.047). Bevacizumab progression-free survival with early and delayed use was 3.45 and 2.92 months, respectively (p=0.504). Survival time from the start of bevacizumab was 6.18 months in patients with early administration, and 6.47 in the delayed administration one (p=0.318). Conclusion: Delayed administration of bevacizumab can be considered in selected patients with less aggressive recurrent glioblastoma. ER -